ArticleACS omega2026
Preparation and Characterization of Niosomes Containing Cationic Antimicrobial Peptides WSKK11 and WSRR11.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Niosomal vesicles were formulated to encapsulate the antimicrobial peptides WSKK11-(K) and WSRR11 (R), using thin film (TF) hydration and reverse-phase evaporation (ReF). Drug entrapment efficiency was determined by high-performance liquid chromatography and Fourier transform infrared spectroscopy. Particle characterization included photon correlation spectrophotometry (Zetasizer), light and inverted microscopy, transmission electron microscopy (TEM), and scanning electron microscopy (SEM). The antimicrobial and cytotoxic activities of the niosomes were also evaluated. FTIR investigation showed that WSKK11 and WSRR11 could be successfully encapsulated. KTF and RTF encapsulated about 83.93 ± 0.15% of WSKK11 and 88.58 ± 9.92% of WSRR11, while KReF and RReF encapsulated 88.72 ± 9.78 and 89.36 ± 9.22%, respectively. Thin film hydration (CTF-control, KTF, and RTF) exhibited a mean particle size of 1.28-2.02 μm with size distribution (PDI = 0.40-0.45) and zeta potential (-44.2 to -47.3), while reverse-phase evaporation (CReF-control, KReF, and RReF) gave a mean particle size of 0.75-1.84 μm with size distribution (PDI = 0.16-0.48) and zeta potential (-49.4 to -60.8). The niosomes exhibited spherical structures within the micrometer-scale range, as observed by TEM and SEM analyses. Analyses revealed a low cytotoxicity against human keratinocyte HaCaT and fibroblast MRC-5 cells. Therefore, these results provide proof of principle for the effective use of niosomes as a delivery vehicle for antimicrobial peptides to treat acne-causing bacteria.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.